Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 May;27(5):506-11.
doi: 10.3346/jkms.2012.27.5.506. Epub 2012 Apr 25.

Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting

Se Won Oh  1 , Ho Jun Chin, Dong Wan Chae, Ki Young Na
Affiliations
Randomized Controlled Trial

Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting

Se Won Oh et al. J Korean Med Sci. 2012 May.

Abstract

Previous studies reported the beneficial effect of erythropoietin (EPO) in acute injuries. We followed patients with and without acute kidney injury (AKI) after coronary artery bypass grafting (CABG) and evaluated the effect of EPO on long-term outcome. We also assessed the efficacy of urinary neutrophil gelatinase-associated lipocalin (uNGAL) as a predictive marker of AKI. Seventy-one patients scheduled for elective CABG were randomly given either 300 U/kg of EPO or saline before CABG. The primary outcome was AKI, and the secondary outcome was the all-cause-mortality and composite of all-cause-mortality and end stage renal disease (ESRD). Twenty-one patients had AKI, 14 (66.7%) in the placebo group and 7 (33.3%) in the EPO group (P = 0.05). Also, uNGAL was higher in the patients with AKI than in those without AKI at baseline, 2, 4, 24, and 72 hr after CABG (P = 0.011). Among patients with AKI, 2-week creatinine (Cr) was not different from baseline Cr in the EPO group, but 2-week Cr was significantly higher than baseline Cr in the placebo group (P = 0.009). All-cause-mortality (P = 0.022) and the composite of all-cause-mortality and ESRD (P = 0.003) were reduced by EPO. EPO reduces all-cause-mortality and ESRD in patients with AKI, largely due to the beneficial effect of EPO on recovery after AKI.

Keywords: Erythropoietin; Mortality; Neutrophil Gelatinase-Associated Lipocalin Protein.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Changes of serum creatinine after coronary artery bypass grafting in patients with AKI. *P < 0.05 vs 0 days, both EPO and placebo group; †P < 0.05 vs 0 days, placebo group only. Error bars show the standard deviation of mean.
Fig. 2
Fig. 2
Kaplan-Meier curves for composite outcome of mortality or ESRD. Participants were classified according to the development of AKI and the administration of EPO: group A, AKI in EPO group; group B, no AKI in placebo group; group C, no AKI in EPO group; group D, AKI in placebo group.
See this image and copyright information in PMC

References

    1. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, Doe BG, Ferguson DJ, Johnson MH, Ratcliffe PJ. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int. 1993;44:1149–1162. - PubMed
    1. Weidemann A, Johnson RS. Nonrenal regulation of EPO synthesis. Kidney Int. 2009;75:682–688. - PubMed
    1. Warren JS, Zhao Y, Yung R, Desai A. Recombinant human erythropoietin suppresses endothelial cell apoptosis and reduces the ratio of Bax to Bcl-2 proteins in the aortas of apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2011;57:424–433. - PMC - PubMed
    1. Toba H, Nakashima K, Oshima Y, Kojima Y, Tojo C, Nakano A, Wang J, Kobara M, Nakata T. Erythropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond haematopoiesis. Clin Exp Pharmacol Physiol. 2010;37:1139–1146. - PubMed
    1. Malgorzewicz S, Lichodziejewska-Niemierko M, Lizakowski S, Liberek T, Lysiak-Szydlowska W, Rutkowski B. Oxidative stress, inflammation and nutritional status during darbepoetin alpha treatment in peritoneal dialysis patients. Clin Nephrol. 2010;73:210–215. - PubMed

Publication types

MeSH terms